Default company panoramic image

TechnoVax Inc.

We create Novel Vaccines with no current alternatives by achieving Ground-breaking Clinical Solutions: i.e. Universal Flu & Inhaled Powder.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Tarrytown, NY, USA
  • Currency USD
  • Founded December 2004
  • Employees 6
  • Website

Company Summary

We have developed a next-generation technology platform based on bio-engineered Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry and the scientific community strongly believe that VLP based vaccines are the Technology of the Future!


  • Default avatar
    Jose M. Galarza (DVM, PhD)
    Chief Executive Officer

    Dr. Galarza is the Founder of TechnoVax with more than 30 years of scientific experience in the field of virology and vaccine development. While at Wyeth Pharma, Dr. Galarza and his team invented the “Influenza Virus-Like Particle” technology. Prior Wyeth, he held research positions at UC Irvine and the University of Utah . He received Doctorates in Veterinary Medicine and in Microbiology from the University of La Plata in Argentina.

  • Default avatar
    Hector Munoz
    Chief Financial & Corporate Development Officer

    Mr. Hector Munoz (MBA) is the CFO and Corporate Development Officer of TechnoVax. He brings over 20 years of domestic and international corporate experience. Mr. Munoz has held senior management positions in Business Development, Corporate M&A and Trade Marketing with R.J. Reynolds Int’l and with JT Int’l, during which time he has orchestrated multi- million dollar corporate M&A projects, ranging from divestitures to international joint-ventures.

  • Default avatar
    George Martin
    Chief Technical Officer

    Dr. George Martin (PhD) is a co-founder and the Chief Technical Officer and co-founder of TechnoVax. He is Scientist Emeritus at the National Institutes of Health and former Senior Vice President for Scientific Affairs of Fibrogen, Inc. in San Francisco.


  • Default avatar
    Pasternak Patent Law / Leason Ellis LLP
    Default avatar
    Cronin and Hanley, LLC

Previous Investors

  • Default avatar